Brokerages forecast that Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) will report earnings per share of $0.81 for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Valeant Pharmaceuticals Intl’s earnings, with estimates ranging from $0.71 to $0.91. Valeant Pharmaceuticals Intl posted earnings of $1.05 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 22.9%. The business is scheduled to announce its next earnings results on Tuesday, August 14th.
On average, analysts expect that Valeant Pharmaceuticals Intl will report full year earnings of $3.36 per share for the current fiscal year, with EPS estimates ranging from $3.00 to $3.76. For the next fiscal year, analysts forecast that the business will post earnings of $3.54 per share, with EPS estimates ranging from $3.31 to $3.94. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Valeant Pharmaceuticals Intl.
Get Valeant Pharmaceuticals Intl alerts:Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last released its quarterly earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported $0.89 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.60 by $0.29. Valeant Pharmaceuticals Intl had a negative net margin of 10.65% and a positive return on equity of 27.87%. The business had revenue of $2 billion for the quarter, compared to analyst estimates of $1.95 billion. During the same quarter in the previous year, the business earned $1.79 earnings per share. The firm’s revenue was down 5.4% compared to the same quarter last year.
VRX has been the topic of a number of recent analyst reports. Mizuho upgraded shares of Valeant Pharmaceuticals Intl from an “underperform” rating to a “neutral” rating and boosted their price target for the company from $10.00 to $15.00 in a report on Friday, April 6th. Barclays upgraded shares of Valeant Pharmaceuticals Intl from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $20.00 to $34.00 in a report on Wednesday, June 6th. Zacks Investment Research upgraded shares of Valeant Pharmaceuticals Intl from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. Deutsche Bank set a $20.00 price target on shares of Valeant Pharmaceuticals Intl and gave the company a “buy” rating in a report on Wednesday, March 21st. Finally, TD Securities lowered shares of Valeant Pharmaceuticals Intl from a “buy” rating to a “hold” rating and set a $24.00 price target on the stock. in a report on Friday, June 22nd. Five analysts have rated the stock with a sell rating, eleven have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Valeant Pharmaceuticals Intl currently has an average rating of “Hold” and a consensus price target of $21.43.
In other Valeant Pharmaceuticals Intl news, Director Schutter Richard U. De purchased 15,000 shares of the company’s stock in a transaction dated Tuesday, May 15th. The shares were bought at an average price of $21.83 per share, for a total transaction of $327,450.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 11.54% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in VRX. Envestnet Asset Management Inc. increased its stake in shares of Valeant Pharmaceuticals Intl by 189.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 5,991 shares of the specialty pharmaceutical company’s stock worth $103,000 after purchasing an additional 3,921 shares during the last quarter. Prime Capital Investment Advisors LLC acquired a new position in shares of Valeant Pharmaceuticals Intl during the 4th quarter worth $142,000. Assetmark Inc. increased its stake in shares of Valeant Pharmaceuticals Intl by 409.4% during the 1st quarter. Assetmark Inc. now owns 11,498 shares of the specialty pharmaceutical company’s stock worth $183,000 after purchasing an additional 9,241 shares during the last quarter. First Allied Advisory Services Inc. increased its stake in shares of Valeant Pharmaceuticals Intl by 33.6% during the 1st quarter. First Allied Advisory Services Inc. now owns 15,101 shares of the specialty pharmaceutical company’s stock worth $242,000 after purchasing an additional 3,800 shares during the last quarter. Finally, Zweig DiMenna Associates LLC acquired a new position in shares of Valeant Pharmaceuticals Intl during the 1st quarter worth $245,000. Institutional investors own 46.95% of the company’s stock.
Shares of VRX stock traded up $0.25 during trading hours on Tuesday, reaching $23.80. 3,875,654 shares of the stock traded hands, compared to its average volume of 10,085,823. Valeant Pharmaceuticals Intl has a 1-year low of $10.94 and a 1-year high of $27.79. The company has a debt-to-equity ratio of 5.59, a current ratio of 1.18 and a quick ratio of 0.92. The firm has a market capitalization of $8.02 billion, a P/E ratio of 6.15, a P/E/G ratio of 0.35 and a beta of -0.38.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.
Get a free copy of the Zacks research report on Valeant Pharmaceuticals Intl (VRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment